|
US5607925A
(en)
*
|
1988-11-15 |
1997-03-04 |
Merrell Pharmaceuticals Inc. |
Treatment of carcinoma by administration of 2'-halomethylidenyl-2'-deoxynucleosides
|
|
US5026687A
(en)
|
1990-01-03 |
1991-06-25 |
The United States Of America As Represented By The Department Of Health And Human Services |
Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds
|
|
UA6419A1
(uk)
|
1991-01-03 |
1994-12-29 |
Чеслав-Констянтин Альбінович Будревич |
Вітродвигун будревича
|
|
WO1994001125A1
(en)
|
1992-07-13 |
1994-01-20 |
Sherman Kenneth E |
Composition and method of treating hepatitis b
|
|
IS2334B
(is)
|
1992-09-08 |
2008-02-15 |
Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) |
Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
|
|
US6107027A
(en)
|
1994-12-14 |
2000-08-22 |
University Of Washington |
Ribozymes for treating hepatitis C
|
|
GB9505025D0
(en)
|
1995-03-13 |
1995-05-03 |
Medical Res Council |
Chemical compounds
|
|
US6387365B1
(en)
|
1995-05-19 |
2002-05-14 |
Schering Corporation |
Combination therapy for chronic hepatitis C infection
|
|
US6043358A
(en)
|
1995-11-01 |
2000-03-28 |
Merck & Co., Inc. |
Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases
|
|
US5980884A
(en)
|
1996-02-05 |
1999-11-09 |
Amgen, Inc. |
Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon
|
|
GB9605293D0
(en)
|
1996-03-13 |
1996-05-15 |
Glaxo Group Ltd |
Medicaments
|
|
US5922757A
(en)
|
1996-09-30 |
1999-07-13 |
The Regents Of The University Of California |
Treatment and prevention of hepatic disorders
|
|
AU5157998A
(en)
|
1996-11-01 |
1998-05-29 |
Thomas Najarian |
Methods and compositions for treatment of hepatitis c infection
|
|
IL119833A
(en)
|
1996-12-15 |
2001-01-11 |
Lavie David |
Hypericum perforatum extracts for the preparation of pharmaceutical compositions for the treatment of hepatitis
|
|
US6103706A
(en)
|
1997-04-29 |
2000-08-15 |
New York Blood Center, Inc. |
Methods for treating viral infections
|
|
US6010890A
(en)
|
1997-04-29 |
2000-01-04 |
New York Blood Center, Inc. |
Method for viral inactivation and compositions for use in same
|
|
US6143752A
(en)
|
1997-08-01 |
2000-11-07 |
Oren; Ran |
Method for preventing or arresting liver damage in humans
|
|
GB9718913D0
(en)
|
1997-09-05 |
1997-11-12 |
Glaxo Group Ltd |
Substituted oxindole derivatives
|
|
DK1136075T3
(da)
|
1997-09-21 |
2003-04-28 |
Schering Corp |
Kombinationsterapi til udryddelse aff detekterbart HCV-RNA i patienter med kronisk hepatitis C infektion
|
|
US6455051B1
(en)
|
1997-10-13 |
2002-09-24 |
Otsuka Pharmaceutical Co., Ltd. |
Ameliorant for hepatitis C therapeutic effect and application thereof
|
|
FR2771637B1
(fr)
|
1997-12-01 |
2003-10-24 |
Hutchinson |
Utilisation d'un halogenure de dialkyldialkylammonium par voie parenterale dans les infections bacteriennes et virales
|
|
BR9813508A
(pt)
|
1997-12-11 |
2000-10-03 |
Univ Oxford |
Inibição de replicação viral associada com membrana
|
|
AU1703799A
(en)
|
1997-12-17 |
1999-07-05 |
Cornell Research Foundation Inc. |
Cyclooxygenase-2 inhibition
|
|
US7462605B2
(en)
|
1998-01-23 |
2008-12-09 |
Celmed Oncology (Usa), Inc. |
Phosphoramidate compounds and methods of use
|
|
EP1053243B1
(en)
|
1998-02-12 |
2011-03-30 |
Emory University |
Sphingolipid derivatives and their methods of use
|
|
CA2326535A1
(en)
|
1998-03-27 |
1999-10-07 |
Regents Of The University Of Minnesota |
Nucleosides with antiviral and anticancer activity
|
|
JP2000007578A
(ja)
|
1998-06-24 |
2000-01-11 |
Hiroaki Okushin |
C型肝炎ウイルスの陰性化のための投薬システム
|
|
PT1091975E
(pt)
|
1998-07-01 |
2006-05-31 |
Debiopharm Sa |
Nova ciclosporina com um perfil de actividade melhorado
|
|
RU2158604C2
(ru)
|
1998-07-03 |
2000-11-10 |
Толоконская Наталья Петровна |
Способ лечения вирусного гепатита c
|
|
US6323180B1
(en)
|
1998-08-10 |
2001-11-27 |
Boehringer Ingelheim (Canada) Ltd |
Hepatitis C inhibitor tri-peptides
|
|
US6403564B1
(en)
|
1998-10-16 |
2002-06-11 |
Schering Corporation |
Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
|
|
JP2002527522A
(ja)
|
1998-10-16 |
2002-08-27 |
シェリング・コーポレーション |
慢性C型肝炎感染を有する患者における検出可能HCV−RNA根絶用リバビリン−インターフェロン−α併用療法
|
|
US20080275005A1
(en)
|
1998-11-25 |
2008-11-06 |
Murphy Michael P |
Mitochondrially targeted antioxidants
|
|
AU2156900A
(en)
|
1998-12-18 |
2000-07-12 |
Schering Corporation |
Ribavirin-interferon alfa induction hcv combination therapy
|
|
AR021876A1
(es)
|
1998-12-18 |
2002-08-07 |
Schering Corp |
Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado
|
|
US6824768B2
(en)
|
1998-12-18 |
2004-11-30 |
Schering Corporation |
Ribavirin-pegylated interferon alfa induction HCV combination therapy
|
|
JP2000212099A
(ja)
|
1999-01-19 |
2000-08-02 |
Mochida Pharmaceut Co Ltd |
ウイルス性肝炎治療剤
|
|
BR0008211A
(pt)
|
1999-02-13 |
2001-11-06 |
Purepulse Technologies Inc |
Métodos para reduzir o teor de um patógeno presente em uma composição biologicamente derivada, e para inativar um vìrus presente em uma composição biologicamente derivada, e, composição biologicamente derivada contendo uma biomolécula de interesse
|
|
US6589570B1
(en)
|
1999-04-12 |
2003-07-08 |
University Of Madras |
Pharmaceutical formulation useful for the treatment of hepatitis B, hepatitis C and other viral infections of the liver and a process for its preparation
|
|
US6849254B1
(en)
|
1999-04-19 |
2005-02-01 |
Schering Corporation |
HCV combination therapy
|
|
CN1390227A
(zh)
|
1999-07-22 |
2003-01-08 |
新生物生物公司 |
酶催化的治疗活化
|
|
WO2001012214A2
(en)
|
1999-08-13 |
2001-02-22 |
F. Hoffmann-La Roche Ag |
MYCOPHENOLATE MOFETIL IN ASSOCIATION WITH PEG-IFN-$g(a)
|
|
US20050245502A1
(en)
|
1999-08-23 |
2005-11-03 |
Phoenix Biosciences |
Treatments for viral infections
|
|
US6369087B1
(en)
|
1999-08-26 |
2002-04-09 |
Robert R. Whittle |
Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
|
|
KR100392292B1
(ko)
|
2000-01-07 |
2003-07-22 |
주식회사 펩트론 |
5원환 융합 방향족 헤테로사이클릭 화합물을 유효성분으로 하는 hcv 치료제 조성물
|
|
WO2001077091A2
(en)
|
2000-04-05 |
2001-10-18 |
Tularik Inc. |
Ns5b hcv polymerase inhibitors
|
|
US7018796B2
(en)
|
2000-04-07 |
2006-03-28 |
Shionogi & Co., Ltd. |
Preincubation assay methods
|
|
CA2406140A1
(en)
|
2000-04-18 |
2001-10-25 |
Virco Bvba |
Methods for measuring drug resistance
|
|
US6415797B1
(en)
|
2000-07-07 |
2002-07-09 |
First Circle Medical, Inc. |
Treatment of human herpesviruses using hyperthermia
|
|
US7244721B2
(en)
|
2000-07-21 |
2007-07-17 |
Schering Corporation |
Peptides as NS3-serine protease inhibitors of hepatitis C virus
|
|
CN1498224A
(zh)
|
2000-07-21 |
2004-05-19 |
���鹫˾ |
用作丙型肝炎病毒ns3-丝氨酸蛋白酶抑制剂的新型肽
|
|
EP1325324A4
(en)
|
2000-08-02 |
2004-11-10 |
Ortho Mcneil Pharm Inc |
IMPROVED ANTIVIRAL AND ANTI-CANCER CHEMOTHERAPY USING ERYTHROPOIETIN ADMINISTRATION (EPO)
|
|
RO118842B1
(ro)
|
2000-08-02 |
2003-12-30 |
Cristian Paul Munteanu |
Metodă de tratament a limfoamelor maligne nonhodgkin de mică malignitate, asociate cu boală cronică de ficat de etiologie virală c
|
|
SV2003000617A
(es)
|
2000-08-31 |
2003-01-13 |
Lilly Co Eli |
Inhibidores de la proteasa peptidomimetica ref. x-14912m
|
|
ATE338564T1
(de)
|
2000-10-12 |
2006-09-15 |
Viromics Gmbh |
Proteasome inhibitoren zur behandlung von hepatitis-virus infektionen
|
|
IL155414A0
(en)
|
2000-10-13 |
2003-11-23 |
Univ Monash |
Disease prevention by reactivation of the thymus
|
|
EP1326594A2
(en)
|
2000-10-18 |
2003-07-16 |
Schering Corporation |
Ribavirin-pegylated interferon alfa hcv combination therapy
|
|
FR2815543B1
(fr)
|
2000-10-19 |
2003-10-24 |
Sedat |
Seringue d'auto-injection d'un melange extemporane
|
|
WO2002055100A2
(en)
|
2000-10-20 |
2002-07-18 |
Genetics Institute, Llc |
Method and composition for inhibition of tumor growth and enhancing an immune response
|
|
AU2001297817A1
(en)
|
2000-11-08 |
2002-11-25 |
Eli Lilly And Company |
Antiviral therapies using polyamine or polyamine analog-amino acid conjugates
|
|
WO2002053096A2
(en)
|
2000-12-06 |
2002-07-11 |
The Trustees Of The University Of Pennsylvania |
Single therapy and combination therapy involving drugs with target cellular proteins and drugs which target pathogen-encoded proteins
|
|
US7105499B2
(en)
|
2001-01-22 |
2006-09-12 |
Merck & Co., Inc. |
Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
|
|
WO2002057425A2
(en)
|
2001-01-22 |
2002-07-25 |
Merck & Co., Inc. |
Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
|
|
CN1245215C
(zh)
|
2001-02-28 |
2006-03-15 |
四川省生物工程研究中心 |
重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂
|
|
GB0107924D0
(en)
|
2001-03-29 |
2001-05-23 |
Angeletti P Ist Richerche Bio |
Inhibitor of hepatitis C virus NS3 protease
|
|
US6673775B2
(en)
|
2001-04-18 |
2004-01-06 |
Schering Corporation |
Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
|
|
US7326536B2
(en)
|
2001-05-03 |
2008-02-05 |
Eli Lilly And Company |
Agents for treatment of HCV and methods of use
|
|
US6833351B2
(en)
|
2001-05-21 |
2004-12-21 |
Douglas T. Dieterich |
Method of treating anemia caused by ribavirin treatment of hepatitis C using erythropoietin alpha
|
|
US20030138403A1
(en)
|
2001-06-29 |
2003-07-24 |
Maxygen Aps |
Interferon formulations
|
|
JP2004522803A
(ja)
|
2001-06-29 |
2004-07-29 |
マキシゲン・エイピーエス |
インターフェロン製剤
|
|
JP2004535464A
(ja)
|
2001-07-20 |
2004-11-25 |
インターミューン インコーポレイテッド |
肝臓の線維症を治療する方法
|
|
WO2003024461A1
(en)
|
2001-09-20 |
2003-03-27 |
Schering Corporation |
Hcv combination therapy
|
|
PL369129A1
(en)
|
2001-09-28 |
2005-04-18 |
Intermune, Inc. |
Method for treating hepatitis c virus infection in treatment failure patients
|
|
HUP0401659A3
(en)
|
2001-09-28 |
2005-02-28 |
Intermune Inc Brisbane |
Method for treating hepatitis c virus infection in treatment failure patients
|
|
MXPA04003238A
(es)
|
2001-10-05 |
2004-07-08 |
Intermune Inc |
Metodo para tratar la infeccion de virus de hepatitis con una configuracion de suministro de interferon multifasica.
|
|
WO2003037908A1
(en)
|
2001-10-31 |
2003-05-08 |
Ribapharm Inc. |
Antiviral combination therapy and compositions
|
|
AR037131A1
(es)
|
2001-10-31 |
2004-10-20 |
Schering Corp |
Formulaciones de jarabe de ribavirina
|
|
EP1444330A1
(en)
|
2001-11-07 |
2004-08-11 |
Kirin Beer Kabushiki Kaisha |
Expansion of t cells in vitro and expanded t cell populations
|
|
AUPR879601A0
(en)
|
2001-11-09 |
2001-12-06 |
Biota Scientific Management Pty Ltd |
Novel chemical compounds and their use
|
|
JP2005517648A
(ja)
|
2001-12-07 |
2005-06-16 |
インターミューン インコーポレイテッド |
肝炎ウイルス感染症を治療するための組成物および方法
|
|
EP1321463B1
(en)
|
2001-12-21 |
2007-08-08 |
Virochem Pharma Inc. |
Thiazole derivatives and their use for the treatment or prevention of Flavivirus infections
|
|
US6906190B2
(en)
|
2002-01-04 |
2005-06-14 |
Ribapharm Inc. |
Inhibitors for de novo-RNA polymerases and methods of identifying targets for same
|
|
RU2212248C1
(ru)
|
2002-01-21 |
2003-09-20 |
Государственное образовательное учреждение высшего профессионального образования Санкт-Петербургская государственная медицинская академия им. И.И. Мечникова |
Способ лечения больных хроническим вирусным гепатитом c
|
|
US20040048795A1
(en)
|
2002-02-26 |
2004-03-11 |
North Shore-Long Island Jewish Research Institute |
Inhibition of inflammatory cytokine production by stimulation of brain muscarinic receptors
|
|
CA2383243A1
(en)
|
2002-04-23 |
2003-10-23 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Method for inhibiting fibrogenesis
|
|
MY140680A
(en)
|
2002-05-20 |
2010-01-15 |
Bristol Myers Squibb Co |
Hepatitis c virus inhibitors
|
|
AU2003249659A1
(en)
|
2002-05-31 |
2003-12-19 |
Schering Corporation |
Combination therapy for rna virus infections involving ribavirin and impdh inhibitors
|
|
TWI334785B
(en)
|
2002-06-03 |
2010-12-21 |
Serono Lab |
Use of recombinant ifn-β1a and pharmaceutical composition comprising recombinant ifn-β1a for the treatment of hcv infection in patients of asian race
|
|
US7608600B2
(en)
|
2002-06-28 |
2009-10-27 |
Idenix Pharmaceuticals, Inc. |
Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
|
|
ES2350687T3
(es)
|
2002-07-03 |
2011-01-26 |
Ono Pharmaceutical Co., Ltd. |
Composiciones de inmunopotenciación.
|
|
ITMI20021860A1
(it)
|
2002-08-28 |
2004-02-29 |
Scalia Antonio Cassar |
Impiego dei triptani come agenti antivirali.
|
|
US7902203B2
(en)
|
2002-11-01 |
2011-03-08 |
Abbott Laboratories, Inc. |
Anti-infective agents
|
|
WO2004039996A1
(en)
|
2002-11-01 |
2004-05-13 |
Cadila Healthcare Limited |
Mthod for producing recombinant human interferon alpha 2b polypeptide in pichia pastoris
|
|
WO2004043435A2
(en)
|
2002-11-13 |
2004-05-27 |
Control Delivery Systems, Inc. |
Systemic delivery of antiviral agents
|
|
WO2004047673A2
(en)
|
2002-11-21 |
2004-06-10 |
Novacea, Inc. |
Treatment of liver disease with active vitamin d compounds
|
|
BRPI0407587A
(pt)
|
2003-02-18 |
2006-02-14 |
Pfizer |
inibidores do vìrus da hepatite c, composições e tratamentos que os utilizam
|
|
WO2004078127A2
(en)
|
2003-02-28 |
2004-09-16 |
Intermune, Inc. |
Continuous delivery methods for treating hepatitis virus infection
|
|
AU2003225670A1
(en)
|
2003-02-28 |
2004-09-28 |
Intermune, Inc. |
Interferon drug therapy for the treatment of viral diseases and liver fibrosis
|
|
EP1601368A2
(en)
|
2003-02-28 |
2005-12-07 |
Intermune, Inc. |
Methods and compositions for treatment of viral diseases
|
|
TWI269656B
(en)
|
2003-03-05 |
2007-01-01 |
Original Image Co Ltd |
Therapeutical composition for hepatitis C
|
|
UA64191A
(en)
|
2003-03-14 |
2004-02-16 |
Yevhenii Mykhailovych Neiko |
Method for treating chronic hepatitises of various etiology
|
|
US20040198840A1
(en)
|
2003-04-02 |
2004-10-07 |
Deloach Reuben Edwin |
Hydrazide substrate safely shuts down disease activated protease to halt viral replication, cancerous cell division, and toxic protein generation
|
|
ES2320771T3
(es)
|
2003-04-16 |
2009-05-28 |
Bristol-Myers Squibb Company |
Inhibidores peptidicos de isoquinolina macrociclicos del virus de la hepatitis c.
|
|
US20040258663A1
(en)
|
2003-05-08 |
2004-12-23 |
Nastech Pharmaceutical Company Inc. |
Compositions and methods for enhanced mucosal delivery of interferon alpha
|
|
US20050009877A1
(en)
|
2003-05-15 |
2005-01-13 |
Henry Lu |
Methods of identifying HCV NS5B polymerase inhibitors and their uses
|
|
AU2004240704B9
(en)
|
2003-05-21 |
2009-10-22 |
Boehringer Ingelheim International Gmbh |
Hepatitis C inhibitor compounds
|
|
EP2345657A1
(en)
|
2003-05-30 |
2011-07-20 |
Pharmasset, Inc. |
Modified fluorinated nucleoside analogues
|
|
US20050187170A1
(en)
|
2003-06-16 |
2005-08-25 |
Biocryst Pharmaceuticals, Inc. |
Enhancing the efficiency of RNA polymerase inhibitors by using inosine monophosphate dehydrogenase inhibitors
|
|
WO2004112720A2
(en)
|
2003-06-20 |
2004-12-29 |
Viral Genomix, Inc. |
Antiviral compositions and methods of using the same
|
|
WO2005010143A2
(en)
|
2003-07-11 |
2005-02-03 |
Oregon Health And Science University |
Methods of treatment and disgnosis using modulators of virus-induced cellular gene sequences
|
|
MD2549G2
(ro)
|
2003-07-18 |
2005-08-31 |
Национальный Научно-Практический Центр Превентивной Медицины Министерства Здравоохранения Республики Молдова |
Metodă de tratament a hepatitei virale cronice C.
|
|
GB0317009D0
(en)
|
2003-07-21 |
2003-08-27 |
Univ Cardiff |
Chemical compounds
|
|
WO2005018330A1
(en)
|
2003-08-18 |
2005-03-03 |
Pharmasset, Inc. |
Dosing regimen for flaviviridae therapy
|
|
EP1667694B1
(en)
|
2003-09-05 |
2010-04-28 |
Anadys Pharmaceuticals, Inc. |
Tlr7 ligands for the treatment of hepatitis c
|
|
WO2005023289A1
(ja)
|
2003-09-08 |
2005-03-17 |
Intellectual Property Consulting Incorporated |
慢性c型肝炎を治療するための医薬組成物
|
|
AR045870A1
(es)
|
2003-10-11 |
2005-11-16 |
Vertex Pharma |
Terapia de combinacion para la infeccion de virus de hepatitis c
|
|
WO2005038056A1
(en)
|
2003-10-14 |
2005-04-28 |
Intermune, Inc. |
Combination therapy for the treatment of viral diseases
|
|
US7491794B2
(en)
|
2003-10-14 |
2009-02-17 |
Intermune, Inc. |
Macrocyclic compounds as inhibitors of viral replication
|
|
HRP20130098T1
(hr)
|
2003-10-14 |
2013-02-28 |
F. Hoffmann - La Roche Ag |
MAKROCIKLIÄŚKE KARBOKSILNE KISELINE I ACILSULFONAMIDNI SPOJEVI KAO INHIBITORI REPLIKACIJE HCV-a
|
|
US20050085528A1
(en)
|
2003-10-17 |
2005-04-21 |
Pfizer Inc. |
Parmaceutical
|
|
EP1692516B1
(en)
|
2003-10-24 |
2010-12-01 |
Immunaid Pty Ltd |
Method of therapy
|
|
US8187874B2
(en)
|
2003-10-27 |
2012-05-29 |
Vertex Pharmaceuticals Incorporated |
Drug discovery method
|
|
CA2543696A1
(en)
|
2003-10-27 |
2005-05-12 |
Vertex Pharmaceuticals Incorporated |
Combinations for hcv treatment
|
|
UA68233A
(en)
|
2003-11-25 |
2004-07-15 |
Univ Zaporizhia State Medical |
Method for treating chronic hepatitis c
|
|
US7078064B2
(en)
|
2003-12-03 |
2006-07-18 |
George Zabrecky |
Compositions and methods useful for treating and preventing chronic liver disease, chronic HCV infection and non-alcoholic steatohepatitis
|
|
NZ595000A
(en)
|
2003-12-22 |
2013-03-28 |
Gilead Sciences Inc |
Imidazo[4,5-c]pyridine derivative for treating viral infections
|
|
WO2005067454A2
(en)
|
2003-12-23 |
2005-07-28 |
Valeant Pharmaceuticals North America |
Combination therapy for treating hepatitis c virus infection
|
|
WO2005067963A1
(en)
|
2003-12-23 |
2005-07-28 |
Intermune, Inc. |
Use of polyethylene glycol-modified interferon-alpha in therapeutic dosing regimens
|
|
WO2005062949A2
(en)
|
2003-12-23 |
2005-07-14 |
Intermune, Inc. |
Method for treating hepatitis virus infection
|
|
DE10361944A1
(de)
|
2003-12-31 |
2005-07-28 |
Viromics Gmbh |
Mittel zur Hemmung der Virusreplikation durch Regulation der Proteinfaltung
|
|
EP1718315A4
(en)
|
2004-02-06 |
2008-08-13 |
Univ Monash |
HIGH DOSE USE OF SULFATED POLYSACCHARIDES IN SHORT INTERVALS FOR THE TREATMENT OF INFECTIONS
|
|
EP1730165A1
(en)
|
2004-02-27 |
2006-12-13 |
Schering Corporation |
Inhibitors of hepatitis c virus ns3 protease
|
|
US7977326B2
(en)
|
2004-04-22 |
2011-07-12 |
Howard J Smith |
Supportive treatment of liver disease
|
|
ES2361458T5
(es)
|
2004-05-04 |
2016-04-20 |
The Board Of Trustees Of The Leland Stanford Junior University |
Procedimientos y composiciones para reducir las cantidades de genoma vírico de VHC en una célula diana
|
|
US20050249702A1
(en)
|
2004-05-06 |
2005-11-10 |
Schering Corporation |
(1R,2S,5S)-N-[(1S)-3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[(2S)-2-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide as inhibitor of hepatitis C virus NS3/NS4a serine protease
|
|
JP2008505059A
(ja)
|
2004-05-06 |
2008-02-21 |
コンジュシェム バイオテクノロジーズ インコーポレイティド |
特異的ウイルス標的用化合物
|
|
WO2006016930A2
(en)
|
2004-05-14 |
2006-02-16 |
Intermune, Inc. |
Methods for treating hcv infection
|
|
EP1753775B1
(en)
|
2004-05-25 |
2012-12-26 |
Boehringer Ingelheim International GmbH |
Process for preparing acyclic hcv protease inhibitors
|
|
KR20120039763A
(ko)
|
2004-06-08 |
2012-04-25 |
버텍스 파마슈티칼스 인코포레이티드 |
약학 조성물
|
|
MX2007000503A
(es)
|
2004-07-14 |
2007-03-08 |
Novartis Ag |
Uso de una combinacion de ciclosporina e interferon pegilado para el tratamiento de hepatitis c(hcv).
|
|
CN101023094B
(zh)
|
2004-07-21 |
2011-05-18 |
法莫赛特股份有限公司 |
烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
|
|
EP1627641A1
(en)
|
2004-08-04 |
2006-02-22 |
Victor Eluwa |
Pharmaceutical compositions comprising metal oxides and uses thereof
|
|
US7153848B2
(en)
|
2004-08-09 |
2006-12-26 |
Bristol-Myers Squibb Company |
Inhibitors of HCV replication
|
|
US7348425B2
(en)
|
2004-08-09 |
2008-03-25 |
Bristol-Myers Squibb Company |
Inhibitors of HCV replication
|
|
CA2581930A1
(en)
|
2004-09-27 |
2006-04-06 |
Jane Trepel |
Modulating mxa expression
|
|
BRPI0515494A
(pt)
|
2004-10-01 |
2008-07-29 |
Debiopharm Sa |
uso de [d-meala] 3-[etval] 4-ciclosporina para o tratamento de infecção por hepatite c e composição farmacêutica compreendendo a referida [d-meala] 3-[etval] 4-ciclosporina
|
|
RU2007116265A
(ru)
|
2004-10-01 |
2008-11-10 |
Вертекс Фармасьютикалз Инкорпорейтед (Us) |
Ингибирование протеазы ns3-ns4a вируса hcv
|
|
US7723310B2
(en)
|
2004-10-18 |
2010-05-25 |
Three Rivers Pharmaceuticals, Llc |
Large dose ribavirin formulations
|
|
US20060228333A1
(en)
|
2004-10-20 |
2006-10-12 |
Kye-Hyung Paik |
Methods for control of tumors and chronic infections by modulating immunologically informed carriers homing to tolerogenic organs or tissues
|
|
WO2006043153A2
(en)
|
2004-10-20 |
2006-04-27 |
Michel Xilinas |
Use of zinc and copper chelators for the treatment of viral diseases
|
|
EP1807403A2
(en)
|
2004-10-26 |
2007-07-18 |
Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. |
Tetracyclic indole derivatives as antiviral agents
|
|
TWI437990B
(zh)
|
2004-10-29 |
2014-05-21 |
Vertex Pharma |
Vx-950之醫藥用途
|
|
US7592315B2
(en)
|
2004-11-02 |
2009-09-22 |
Schering Corporation |
Peptide viral entry inhibitors
|
|
WO2006055854A2
(en)
|
2004-11-17 |
2006-05-26 |
Cypress Bioscience, Inc. |
Methods for reducing the side effects associated with mirtazapine treatment
|
|
US20060105063A1
(en)
|
2004-11-18 |
2006-05-18 |
Kent Hann |
Synergic combination of compositions containing aloe vera isolates and their therapeutic application
|
|
CA2589935A1
(en)
|
2004-12-09 |
2006-06-15 |
Regents Of The University Of Minnesota |
Nucleosides with antiviral and anticancer activity
|
|
TW200633718A
(en)
|
2004-12-16 |
2006-10-01 |
Applied Research Systems |
Treatment of hepatitis c in the asian population
|
|
DE102004061746A1
(de)
|
2004-12-22 |
2006-07-06 |
Bayer Healthcare Ag |
Alkinyl-substituierte Thiophene
|
|
EP1674104A1
(en)
|
2004-12-24 |
2006-06-28 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Uridine derivatives as antiviral drugs against a flaviviridae, especially HCV
|
|
EP1679065A1
(en)
|
2005-01-07 |
2006-07-12 |
OctoPlus Sciences B.V. |
Controlled release compositions for interferon based on PEGT/PBT block copolymers
|
|
CN101107264A
(zh)
|
2005-01-17 |
2008-01-16 |
捷瑞尼股份公司 |
C5a受体拮抗剂
|
|
CA2596966A1
(en)
|
2005-02-03 |
2006-08-10 |
Intarcia Therapeutics, Inc. |
Implantable osmotic device for continuous delivery of suspension formulations
|
|
JP2008530124A
(ja)
|
2005-02-09 |
2008-08-07 |
ミジェニックス インコーポレイテッド |
フラビウイルス感染症を処置または予防するための組成物および方法
|
|
US20060198787A1
(en)
|
2005-02-18 |
2006-09-07 |
Larry Blatt |
Biomarkers for predicting liver fibrosis treatment efficacy
|
|
WO2006091610A2
(en)
|
2005-02-23 |
2006-08-31 |
The Brigham And Women's Hospital, Inc. |
Inhibitors of enveloped virus infectivity
|
|
US20090156545A1
(en)
|
2005-04-01 |
2009-06-18 |
Hostetler Karl Y |
Substituted Phosphate Esters of Nucleoside Phosphonates
|
|
US20060229293A1
(en)
|
2005-04-06 |
2006-10-12 |
Addiction Research Institute, Inc. |
Compositions for the treatment of hepatitis C and methods for using compositions for the treatment of hepatitis C
|
|
JP2008538354A
(ja)
|
2005-04-08 |
2008-10-23 |
キメリクス,インコーポレイテッド |
ウイルス感染症およびその他の内科疾患を治療するための化合物、組成物および方法
|
|
US20060293267A1
(en)
|
2005-04-13 |
2006-12-28 |
University Of Massachusetts |
Dual functional oligonucleotides for use as anti-viral agents
|
|
US20060241144A1
(en)
|
2005-04-20 |
2006-10-26 |
Albert Cha |
Method for treating apathy syndrome
|
|
BRPI0610283A2
(pt)
|
2005-05-13 |
2010-10-19 |
Virochem Pharma Inc |
composto, uso do mesmo na preparação de um medicamento para o tratamento ou prevenção de uma infecção por vìrus de hepatite c, composição farmacêutica e combinação farmacêutica
|
|
WO2006127482A1
(en)
|
2005-05-20 |
2006-11-30 |
Bioenvision, Inc. |
Methylene blue therapy of viral disease
|
|
WO2006127289A1
(en)
|
2005-05-20 |
2006-11-30 |
Valeant Research & Development |
Treatment of hcv with subtherapeutic doses of ribavirin
|
|
MX2007014889A
(es)
|
2005-05-26 |
2008-02-19 |
Schering Corp |
Fusion de interferon-inmunoglobulina g.
|
|
WO2006130532A2
(en)
|
2005-05-31 |
2006-12-07 |
Novartis Ag |
Treatment of liver diseases in which iron plays a role in pathogenesis
|
|
US7793040B2
(en)
|
2005-06-01 |
2010-09-07 |
Microsoft Corporation |
Content addressable memory architecture
|
|
US20070004635A1
(en)
|
2005-06-02 |
2007-01-04 |
Schering Corporation |
Method of treating interferon non-responders using HCV protease inhibitor
|
|
WO2006130554A2
(en)
|
2005-06-02 |
2006-12-07 |
Schering Corporation |
Methods of treating hepatitis c virus
|
|
NZ563365A
(en)
|
2005-06-02 |
2011-02-25 |
Schering Corp |
Combination of HCV protease inhibitors with a surfactant
|
|
US20060275366A1
(en)
|
2005-06-02 |
2006-12-07 |
Schering Corporation |
Controlled-release formulation
|
|
US20060287248A1
(en)
|
2005-06-02 |
2006-12-21 |
Schering Corporation |
Asymmetric dosing methods
|
|
NZ563361A
(en)
|
2005-06-02 |
2011-02-25 |
Schering Corp |
HCV protease inhibitors in combination with food
|
|
WO2006130552A2
(en)
|
2005-06-02 |
2006-12-07 |
Schering Corporation |
Methods of treating hepatitis c virus
|
|
US20070232527A1
(en)
|
2005-06-02 |
2007-10-04 |
Anima Ghosal |
Medicaments and methods combining a HCV protease inhibitor and an AKR competitor
|
|
US20070237818A1
(en)
|
2005-06-02 |
2007-10-11 |
Malcolm Bruce A |
Controlled-release formulation of HCV protease inhibitor and methods using the same
|
|
US20060281689A1
(en)
|
2005-06-02 |
2006-12-14 |
Schering Corporation |
Method for modulating activity of HCV protease through use of a novel HCV protease inhibitor to reduce duration of treatment period
|
|
US20060276404A1
(en)
|
2005-06-02 |
2006-12-07 |
Anima Ghosal |
Medicaments and methods combining a HCV protease inhibitor and an AKR competitor
|
|
US20070021351A1
(en)
|
2005-06-02 |
2007-01-25 |
Schering Corporation |
Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor
|
|
US20070207949A1
(en)
|
2005-06-02 |
2007-09-06 |
Anima Ghosal |
Medicaments and methods combining a HCV protease inhibitor and an AKR competitor
|
|
EA016838B1
(ru)
|
2005-06-07 |
2012-07-30 |
Йельский Университет |
Способы лечения рака и других заболеваний или патологических состояний с применением клевудина (lfmau) и телбивудина (ldt)
|
|
RU2293572C1
(ru)
|
2005-07-18 |
2007-02-20 |
Гюнтер Хаазе |
Способ лечения хронического вирусного гепатита с генотип-2 с умеренной активностью
|
|
AR057456A1
(es)
|
2005-07-20 |
2007-12-05 |
Merck & Co Inc |
Inhibidores de la proteasa ns3 del vhc
|
|
PE20070211A1
(es)
|
2005-07-29 |
2007-05-12 |
Medivir Ab |
Compuestos macrociclicos como inhibidores del virus de hepatitis c
|
|
AU2006275413B2
(en)
|
2005-08-02 |
2012-07-19 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of serine proteases
|
|
MX2008001865A
(es)
|
2005-08-12 |
2008-04-15 |
Human Genome Sciences Inc |
Proteinas de fusion de albumina.
|
|
DE102005038768A1
(de)
|
2005-08-16 |
2007-02-22 |
Toximed Gmbh |
Pharmazeutischer Wirkstoff gegen Borreliose
|
|
WO2007022459A2
(en)
|
2005-08-19 |
2007-02-22 |
Vertex Pharmaceuticals Incorporated |
Processes and intermediates
|
|
WO2007030560A2
(en)
|
2005-09-08 |
2007-03-15 |
Philadelphia Health & Education Corporation, D/B/A Drexel University College Of Medicine |
Identification of modulators of serine protease inhibitor kazal and their use as anti-cancer and anti-viral agents
|
|
US7531164B2
(en)
|
2005-10-21 |
2009-05-12 |
Duke University |
Preventing bacterial or viral infectivity and composition containing infection preventing additive
|
|
IE20050723A1
(en)
|
2005-10-28 |
2007-05-30 |
Patrick T Prendergast |
Anti-mineralocorticoid therapy of infection
|
|
WO2007056016A2
(en)
|
2005-11-02 |
2007-05-18 |
Kemia, Inc. |
Bisamide cytokine inhibitors
|
|
RU2306134C2
(ru)
|
2005-11-07 |
2007-09-20 |
Государственное образовательное учреждение высшего профессионального образования "Самарский Государственный медицинский университет" |
Способ базисного лечения хронического вирусного гепатита c
|
|
EP2392589A3
(en)
|
2005-11-11 |
2012-06-20 |
Vertex Pharmaceuticals Incorporated |
Hepatitis C virus variants
|
|
WO2007058384A1
(en)
|
2005-11-17 |
2007-05-24 |
Osaka University |
Method of suppressing replication of hepatitis c virus, inhibitor of replication of the virus and method of screening for the same
|
|
RU2326115C2
(ru)
|
2005-11-21 |
2008-06-10 |
Ефаг АО |
Соли 1-алкиламино-1-дезоксиполиолов с 9-оксоакридин-10-уксусной кислотой, лекарственные препараты на их основе, применение, способы профилактики и лечения
|
|
AR057623A1
(es)
|
2005-11-28 |
2007-12-05 |
Omega Bio Pharma H K Ltd |
Materiales y metodos para el tratamiento de las infecciones virales
|
|
CA2632903C
(en)
|
2005-12-02 |
2015-11-24 |
Vianova Labs, Inc. |
Treatment of cancer and other diseases
|
|
MY150667A
(en)
|
2005-12-09 |
2014-02-28 |
Gilead Pharmasset Llc |
Antiviral nucleosides
|
|
EP1979348B1
(en)
|
2005-12-21 |
2012-01-18 |
Abbott Laboratories |
Anti-viral compounds
|
|
WO2007075896A2
(en)
|
2005-12-22 |
2007-07-05 |
Kemia, Inc. |
Heterocyclic cytokine inhibitors
|
|
RU2306934C1
(ru)
|
2005-12-28 |
2007-09-27 |
ГОУ ВПО Омская Государственная Медицинская Академия |
Способ лечения больных хроническим вирусным гепатитом c
|
|
AP2907A
(en)
|
2006-01-09 |
2014-05-31 |
Romark Lab Lc |
Viral hepatitis treatment
|
|
MD20060037A
(ro)
|
2006-01-24 |
2007-07-31 |
Национальный Научно-Практический Центр Превентивной Медицины Министерства Здравоохранения Республики Молдова |
Metodă de tratament al hepatitei virale acute C
|
|
EP1981524A2
(en)
|
2006-02-09 |
2008-10-22 |
Schering Corporation |
Combinations comprising hcv protease inhibitor(s) and hcv polymerase inhibitor(s), and methods of treatment related thereto
|
|
WO2007092645A2
(en)
|
2006-02-09 |
2007-08-16 |
Schering Corporation |
Novel hcv inhibitor combinations and methods
|
|
AU2007217355B2
(en)
|
2006-02-27 |
2012-06-21 |
Vertex Pharmaceuticals Incorporated |
Co-crystals comprising VX-950 and pharmaceutical compositions comprising the same
|
|
WO2007109080A2
(en)
|
2006-03-16 |
2007-09-27 |
Vertex Pharmaceuticals Incorporated |
Deuterated hepatitis c protease inhibitors
|
|
US20070218138A1
(en)
|
2006-03-20 |
2007-09-20 |
Bittorf Kevin J |
Pharmaceutical Compositions
|
|
TWI428125B
(zh)
|
2006-03-20 |
2014-03-01 |
Vertex Pharma |
對包括vx-950之藥物實施噴霧乾燥之方法及由此方法製備之產物
|
|
WO2007111866A2
(en)
|
2006-03-23 |
2007-10-04 |
Schering Corporation |
Combinations of hcv protease inhibitor(s) and cyp3a4 inhibitor(s), and methods of treatment related thereto
|
|
US8895531B2
(en)
|
2006-03-23 |
2014-11-25 |
Rfs Pharma Llc |
2′-fluoronucleoside phosphonates as antiviral agents
|
|
WO2007130646A2
(en)
|
2006-05-04 |
2007-11-15 |
The Rockefeller University |
Hcv coreceptor and methods of use thereof
|
|
WO2008060695A2
(en)
|
2006-05-22 |
2008-05-22 |
The Trustees Of The University Of Pennsylvania |
Antiviral inhibition of casein kinase ii
|
|
DE102006026464A1
(de)
|
2006-06-01 |
2007-12-06 |
Virologik Gmbh Innovationszentrum Medizintechnik Und Pharma |
Pharmazeutische Zusammensetzung zur Behandlung von Virusinfektionen und / oder Tumorerkrankungen durch Inhibition der Proteinfaltung und des Proteinabbaus
|
|
CA2654183A1
(en)
|
2006-06-02 |
2007-12-13 |
San Diego State University Research Foundation |
Compositions and methods for ameliorating hyperlipidemia
|
|
GB2453068B
(en)
|
2006-06-04 |
2011-03-09 |
Cellartis Ab |
Novel hepatocyte-like cells and hepatoblast-like cells derived from hbs cells
|
|
CA2691214A1
(en)
|
2006-06-09 |
2007-12-21 |
Kemia, Inc. |
Therapy using cytokine inhibitors
|
|
WO2007149382A2
(en)
|
2006-06-19 |
2007-12-27 |
The Cleveland Clinic Foundation |
Therapeutic compositions and methods useful in treating hepatitis
|
|
RU2008152171A
(ru)
|
2006-07-05 |
2010-08-10 |
Интермьюн, Инк. (Us) |
Новые ингибиторы вирусной репликации гепатита с
|
|
US20080081791A1
(en)
|
2006-07-06 |
2008-04-03 |
Weida Huang |
Methods of using combinations of siRNAs for treating a disease or a disorder, and for enhancing siRNA efficacy in RNAi
|
|
TW200819460A
(en)
|
2006-07-07 |
2008-05-01 |
Gilead Sciences Inc |
Antiviral phosphinate compounds
|
|
PT2041156E
(pt)
|
2006-07-13 |
2014-02-21 |
Achillion Pharmaceuticals Inc |
Péptidos 4-amino-4-oxobutanoil como inibidores da replicação viral
|
|
US8329159B2
(en)
|
2006-08-11 |
2012-12-11 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
|
WO2008022006A2
(en)
|
2006-08-11 |
2008-02-21 |
Enanta Pharmaceuticals, Inc. |
Arylalkoxyl hepatitis c virus protease inhibitors
|
|
EP1886685A1
(en)
|
2006-08-11 |
2008-02-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
|
|
US20100158862A1
(en)
|
2006-08-11 |
2010-06-24 |
Bristol-Myers Squibb Company |
Hepatitis C Virus Inhibitors
|
|
US20080131398A1
(en)
|
2006-08-21 |
2008-06-05 |
United Therapeutics Corporation |
Combination therapy for treatment of viral infections
|
|
BRPI0715714A2
(pt)
|
2006-08-25 |
2014-03-11 |
Wyeth Corp |
Métodos para diminuir a frequência de emergência de uma infecção viral de hepatite c resistente ao tratamento, para atrasar a emergência de uma infecção viral de hepatite c resistente ao tratamento, para diminuir o nível de resistência de uma infecção viral de hepatite c resistente ao tratamento, para diminuir a emergência de uma infecção viral de hepatite c resistente a hcv-796, para identificar um indivíduo com uma probabilidade diminuída de responder a uma terapia viral anti-hepatite c, para monitorar, diagnosticar ou prognosticar a infecção viral de hepatite c resistente ao tratamento em um paciente, para monitorar o curso de tratamento de uma infecção viral de hepatite c em um paciente, para prognosticar o desenvolvimento de um ainfecção viral de hepatite c resistente ao tratamento em um paciente, para monitorar a infecção viral de hepatite c em um paciente e para diagnosticar o desenvolvimento de uma infecção viral de hepatite ao tratamento em um paciente
|
|
TW200815384A
(en)
|
2006-08-25 |
2008-04-01 |
Viropharma Inc |
Combination therapy method for treating hepatitis C virus infection and pharmaceutical compositions for use therein
|
|
WO2008073165A2
(en)
|
2006-08-25 |
2008-06-19 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions for identifying anti-hcv agents
|
|
WO2008032227A2
(en)
|
2006-09-11 |
2008-03-20 |
Biomas, Ltd. |
Topical formulations of tellurium-containing compounds
|
|
JP2010503396A
(ja)
|
2006-09-14 |
2010-02-04 |
ヒューマン ジノーム サイエンシーズ, インコーポレイテッド |
アルブミン融合タンパク質
|
|
US20080161324A1
(en)
|
2006-09-14 |
2008-07-03 |
Johansen Lisa M |
Compositions and methods for treatment of viral diseases
|
|
CA2664935A1
(en)
|
2006-09-26 |
2008-04-03 |
Addiction Research Institute, Inc. |
Compositions for the treatment of hepatitis c and methods for using compositions for the treatment of hepatitis c
|
|
US8912321B2
(en)
|
2006-10-10 |
2014-12-16 |
Gilead Pharmasset Llc |
Preparation of nucleosides ribofuranosyl pyrimidines
|
|
US7777395B2
(en)
|
2006-10-12 |
2010-08-17 |
Eastman Kodak Company |
Continuous drop emitter with reduced stimulation crosstalk
|
|
BRPI0718161A2
(pt)
|
2006-10-27 |
2013-11-26 |
Merck & Co Inc |
Composto, composição farmacêutica, e, uso do composto.
|
|
CA2670260A1
(en)
|
2006-11-15 |
2008-05-22 |
Virochem Pharma Inc. |
Thiophene analogues for the treatment or prevention of flavivirus infections
|
|
US20100093824A1
(en)
|
2006-11-29 |
2010-04-15 |
Judith Frydman |
Methods of treating viral infection
|
|
US20100081672A1
(en)
|
2006-12-07 |
2010-04-01 |
Schering Corporation |
Ph sensitive matrix formulation
|
|
RU2336096C1
(ru)
|
2006-12-14 |
2008-10-20 |
ООО Медицинский центр "Столица" |
Способ лечения гепатита с
|
|
RU2345787C2
(ru)
|
2006-12-25 |
2009-02-10 |
Государственное образовательное учреждение высшего профессионального образования "Самарский Государственный медицинский университет" |
Способ лечения хронического вирусного гепатита с
|
|
US20080261913A1
(en)
|
2006-12-28 |
2008-10-23 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of liver disorders
|
|
WO2008086161A1
(en)
|
2007-01-08 |
2008-07-17 |
Phenomix Corporation |
Macrocyclic hepatitis c protease inhibitors
|
|
WO2008089034A2
(en)
|
2007-01-11 |
2008-07-24 |
Kemia, Inc. |
Cytokine inhibitors
|
|
US7645732B2
(en)
|
2007-01-24 |
2010-01-12 |
Board Of Regents, The University Of Texas System |
Treating hepatitis C virus infection
|
|
TWI423968B
(zh)
|
2007-02-01 |
2014-01-21 |
Tibotec Pharm Ltd |
Hcv巨環抑制劑之多晶形
|
|
TW200838550A
(en)
*
|
2007-02-09 |
2008-10-01 |
Novartis Ag |
Organic compounds
|
|
TWI426918B
(zh)
|
2007-02-12 |
2014-02-21 |
Merck Sharp & Dohme |
Il-23拮抗劑於治療感染之用途
|
|
CA2683383C
(en)
|
2007-02-21 |
2016-01-05 |
Allaccem, Incorporated |
Bridged polycyclic compound based compositions for the inhibition and amelioration of disease
|
|
HRP20120330T1
(hr)
|
2007-02-27 |
2012-05-31 |
Vertex Pharmaceuticals Incorporated |
Sukristali i farmaceutski pripravci koji ih sadrže
|
|
WO2008106167A1
(en)
|
2007-02-28 |
2008-09-04 |
Conatus Pharmaceuticals, Inc. |
Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
|
|
MD3477G2
(ro)
|
2007-03-21 |
2008-08-31 |
Николае БОДРУГ |
Metodă de tratament al hepatitei virale cronice C
|
|
WO2008116194A2
(en)
|
2007-03-22 |
2008-09-25 |
Innovative Biologics, Inc. |
Blockers of pore-forming virulence factors and their use as anti-infectives
|
|
DK2308514T3
(da)
|
2007-03-23 |
2013-09-02 |
To Bbb Holding B V |
Konjugater til målrettet lægemiddeltransport gennem blod-hjerne barrieren
|
|
US7964580B2
(en)
|
2007-03-30 |
2011-06-21 |
Pharmasset, Inc. |
Nucleoside phosphoramidate prodrugs
|
|
WO2008124384A2
(en)
|
2007-04-03 |
2008-10-16 |
Aegerion Pharmaceuticals, Inc. |
Combinations of mtp inhibitors with cholesterol absorption inhibitors or interferon for treating hepatitis c
|
|
WO2008133966A1
(en)
|
2007-04-27 |
2008-11-06 |
Chimerix, Inc. |
Methods of reducing nephrotoxicity in subjects administered with nucleoside
|
|
US20080269205A1
(en)
|
2007-04-27 |
2008-10-30 |
Ondine International, Ltd. |
Methods to prevent vertical transmission of infectious diseases
|
|
SG174809A1
(en)
|
2007-05-03 |
2011-10-28 |
Intermune Inc |
Macrocyclic compounds useful as inhibitors of hepatitis c virus
|
|
ES2381410T3
(es)
|
2007-05-04 |
2012-05-28 |
Vertex Pharmceuticals Incorporated |
Terapia de combinación paa el tratamiento de infecciones por VHC
|
|
JP2010526834A
(ja)
|
2007-05-10 |
2010-08-05 |
インターミューン・インコーポレーテッド |
C型肝炎ウイルス複製の新規ペプチド阻害剤
|
|
CN101854936A
(zh)
|
2007-05-21 |
2010-10-06 |
弗特克斯药品有限公司 |
包含vx-950的剂型及其给药方案
|
|
RU2348412C1
(ru)
|
2007-06-01 |
2009-03-10 |
Лариса Леонидовна Попова |
Способ профилактики рецидива хронического вирусного гепатита с после достижения вирусологической ремиссии
|
|
WO2008154248A1
(en)
|
2007-06-06 |
2008-12-18 |
Inova Health System |
Prognostic chronic hepatitis c biomarkers
|
|
NZ582096A
(en)
|
2007-06-29 |
2012-05-25 |
Gilead Sciences Inc |
Antiviral compounds that inhibit hepatitis c virus (hcv)
|
|
CN100532388C
(zh)
|
2007-07-16 |
2009-08-26 |
郑州大学 |
2’-氟-4’-取代-核苷类似物、其制备方法及应用
|
|
EP2175865A4
(en)
|
2007-07-25 |
2012-01-11 |
Biolex Therapeutics Inc |
INTERFERON DRUG PRODUCTS WITH CONTROLLED RELEASE AND TREATMENT OF HCV INFECTIONS THEREWITH
|
|
US7828771B2
(en)
|
2007-07-26 |
2010-11-09 |
Entra Pharmaceuticals, Inc. |
Systems and methods for delivering drugs
|
|
ES2563477T3
(es)
|
2007-08-03 |
2016-03-15 |
Biotron Limited |
Composiciones antivirales para tratar la hepatitis C a base de 5-(1-metilpirazol-4-il)2-naftoilguanidina y 2'-C-metiladenosina o 2'-C-metilcitidina
|
|
US8629171B2
(en)
|
2007-08-08 |
2014-01-14 |
Bristol-Myers Squibb Company |
Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt
|
|
US7728027B2
(en)
|
2007-08-08 |
2010-06-01 |
Bristol-Myers Squibb Company |
Process for synthesizing compounds useful for treating hepatitis C
|
|
WO2009026292A1
(en)
|
2007-08-20 |
2009-02-26 |
Anadys Pharmaceuticals, Inc. |
Dosing methods for treating disease
|
|
NZ583699A
(en)
|
2007-08-30 |
2012-04-27 |
Vertex Pharma |
Co-crystals of vx-950 (telaprevir) other components and pharmaceutical compositions comprising the same
|
|
WO2009033183A2
(en)
|
2007-09-08 |
2009-03-12 |
University Of Florida Research Foundation |
Compounds and methods for treatment of hcv and conditions associated with cd81 binding
|
|
US20090076100A1
(en)
|
2007-09-13 |
2009-03-19 |
Protia, Llc |
Deuterium-enriched gsk625433
|
|
CA2699280A1
(en)
|
2007-09-14 |
2009-03-26 |
Schering Corporation |
Method of treating hepatitis c patients
|
|
SI2368882T1
(sl)
|
2007-09-17 |
2015-02-27 |
Abbvie Bahamas Ltd. |
Antiinfekcijski pirimidini in njihove uporabe
|
|
MY162760A
(en)
|
2007-09-17 |
2017-07-14 |
Abbvie Bahamas Ltd |
Anti-infective agents and uses thereof
|
|
DK2203430T3
(da)
|
2007-09-17 |
2011-09-26 |
Abbott Lab |
N-phenyl-dioxo-hydropyrimidiner anvendelige som inhibitorer for hepatitis C virus (HCV)
|
|
EP2203168B1
(en)
|
2007-09-18 |
2014-07-16 |
Stanford University |
Compositions for treating a flaviviridae family viral infection
|
|
US20090082366A1
(en)
|
2007-09-26 |
2009-03-26 |
Protia, Llc |
Deuterium-enriched telaprevir
|
|
US20090082414A1
(en)
|
2007-09-26 |
2009-03-26 |
Protia, Llc |
Deuterium-enriched viramidine
|
|
JP5486744B2
(ja)
|
2007-10-03 |
2014-05-07 |
サベル コーポレーション |
ムユヨの花、トゲバンレイシの葉、及びウコンの根の抽出物を含む、肝炎を治療するための組成物
|
|
WO2009046369A2
(en)
|
2007-10-05 |
2009-04-09 |
Medtronic, Inc. |
Use of a specific dosage regimen of ifn-alpha and ribavirin for treating hepatitis c
|
|
WO2009061395A2
(en)
|
2007-11-05 |
2009-05-14 |
Vertex Pharmaceuticals Incorporated |
Hcv combination therapies
|
|
PT2219642E
(pt)
|
2007-11-15 |
2011-10-18 |
Madaus Gmbh |
Componente de silibinina para o tratamento de hepatite
|
|
US8202996B2
(en)
|
2007-12-21 |
2012-06-19 |
Bristol-Myers Squibb Company |
Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
|
|
TWI487522B
(zh)
|
2007-12-21 |
2015-06-11 |
賽基艾維洛米斯研究股份有限公司 |
Hcv蛋白酶抑制劑及其用途(一)
|
|
MX2010006659A
(es)
|
2007-12-21 |
2010-07-05 |
Hoffmann La Roche |
Proceso para la preparacion de un macrociclo.
|
|
JP2011508740A
(ja)
|
2007-12-27 |
2011-03-17 |
エピファニー バイオサイエンシズ, インク. |
抗ウイルス化合物
|
|
EP2268811A1
(en)
|
2008-03-07 |
2011-01-05 |
Santaris Pharma A/S |
Pharmaceutical compositions for treatment of microrna related diseases
|
|
JP5283106B2
(ja)
|
2008-03-14 |
2013-09-04 |
国立大学法人 熊本大学 |
C型肝炎ウイルス阻害剤
|
|
US20100009970A1
(en)
|
2008-03-19 |
2010-01-14 |
Combinatorx (Singapore) Pte. Ltd. |
Compositions and methods for treatment of viral diseases
|
|
US20110045001A1
(en)
|
2008-03-28 |
2011-02-24 |
Biontex Laboratories Gmbh |
Transfection results of non-viral gene delivery systems by influencing of the innate immune system
|
|
WO2009134616A2
(en)
|
2008-04-15 |
2009-11-05 |
Intermune, Inc. |
Novel inhibitors of hepatitis c virus replication
|
|
WO2009131696A1
(en)
|
2008-04-23 |
2009-10-29 |
Vertex Pharmaceuticals Incorporated |
Treatment of hepatitis c virus infections with telaprevir (vx-950) in patients non-responsive to treatment with pegylated interfer0n-alpha-2a/2b and ribavirin
|
|
DE102008029669A1
(de)
|
2008-05-16 |
2009-11-19 |
Schlaak, Jörg Friedrich, Prof. Dr. med. |
Neue Therapeutika für die Hepatitis-Therapie
|
|
US20110218512A1
(en)
|
2008-06-03 |
2011-09-08 |
Aethlon Medical, Inc. |
Enhanced antiviral therapy methods and devices
|
|
JP2011522834A
(ja)
|
2008-06-05 |
2011-08-04 |
ザイモジェネティクス リミテッド ライアビリティ カンパニー |
C型肝炎の治療のためのペグ化iii型インターフェロンの使用
|
|
JP2011522862A
(ja)
|
2008-06-10 |
2011-08-04 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
テラプレビル(Telaprevir)投薬養生法
|
|
CN102123706B
(zh)
|
2008-06-17 |
2013-08-14 |
米纳斯吉拉斯联合大学 |
血小板活化因子受体在治疗黄病毒科病毒引起的感染中的用途
|
|
EA019327B1
(ru)
|
2008-07-22 |
2014-02-28 |
Мерк Шарп Энд Домэ Корп. |
Макроциклическое хиноксалиновое соединение в качестве ингибитора протеазы вгс ns3
|
|
EP2323681A4
(en)
|
2008-07-25 |
2012-11-14 |
Univ Colorado |
METHOD FOR TREATING VIRAL DISEASES
|
|
RU2373952C1
(ru)
|
2008-07-30 |
2009-11-27 |
Юрий Михайлович Амбалов |
Способ лечебного питания больных хроническим гепатитом с, получающих комплексную противовирусную терапию
|
|
WO2010015637A1
(en)
|
2008-08-06 |
2010-02-11 |
Novartis Ag |
New antiviral modified nucleosides
|
|
JP2011530519A
(ja)
|
2008-08-06 |
2011-12-22 |
サイクローン・ファーマシューティカルズ・インコーポレイテッド |
免疫調節化合物を用いたc型肝炎の治療または予防の方法
|
|
KR101647520B1
(ko)
|
2008-08-07 |
2016-08-10 |
에프. 호프만-라 로슈 아게 |
거대환식 화합물의 제조 방법
|
|
CA2732777A1
(en)
|
2008-08-07 |
2010-02-11 |
Schering Corporation |
Pharmaceutical formulations of an hcv protease inhibitor in a solid molecular dispersion
|
|
WO2010021681A2
(en)
|
2008-08-18 |
2010-02-25 |
Combinatorx (Singapore) Pte. Ltd. |
Compositions and methods for treatment of viral diseases
|
|
WO2010020676A1
(en)
|
2008-08-20 |
2010-02-25 |
Vib Vzw |
The use of topoisomerase type i inhibitors to treat viral infections
|
|
JP2012501345A
(ja)
|
2008-08-28 |
2012-01-19 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Hcv遺伝子型の分析
|
|
JP5409636B2
(ja)
|
2008-08-29 |
2014-02-05 |
国立大学法人大阪大学 |
抗c型肝炎ウイルス組成物
|
|
WO2010027921A1
(en)
|
2008-09-03 |
2010-03-11 |
Vertex Pharmaceuticals Incorporated |
Co-crystals and pharmaceutical formulations comprising the same
|
|
UY32099A
(es)
|
2008-09-11 |
2010-04-30 |
Enanta Pharm Inc |
Inhibidores macrocíclicos de serina proteasas de hepatitis c
|
|
PL2331538T3
(pl)
|
2008-09-16 |
2014-09-30 |
Boehringer Ingelheim Int |
Krystaliczne postacie 2-tiazolylo-4chinolinyl-oksy-pochodnej, silnego inhibitora HCV
|
|
PE20110343A1
(es)
|
2008-09-17 |
2011-06-25 |
Boehringer Ingelheim Int |
Combinacion de inhibidor de la proteasa ns3 de hcv con interferon y ribavirina
|
|
WO2010031832A2
(en)
|
2008-09-18 |
2010-03-25 |
Ortho-Mcneil-Janssen Pharmaceuticals, Inc |
Synergistic combinations of a macrocyclic inhibitor of hcv and a thiophene-2-carboxylic acid derivative
|
|
EA201170484A1
(ru)
|
2008-09-24 |
2012-03-30 |
Вертекс Фармасьютикалз Инкорпорейтед |
Терапевтический режим лечения гепатита, включающий пэг-интерферон, рибавирин и vx-950
|
|
JP2012503619A
(ja)
|
2008-09-26 |
2012-02-09 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
Hcv感染に対する抗ウイルス治療のための標的としての宿主細胞キナーゼ
|
|
EP2343066A4
(en)
|
2008-09-30 |
2012-08-29 |
Mochida Pharm Co Ltd |
THERAPEUTIC AGENT FOR HEPATITIS C
|
|
EP2341924A4
(en)
|
2008-10-02 |
2013-01-23 |
David Gladstone Inst |
METHOD FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS
|
|
JP2012505233A
(ja)
|
2008-10-08 |
2012-03-01 |
ザ・シャーロット‐メクレンバーグ・ホスピタル・オーソリティ,ドゥーイング・ビジネス・アズ・キャロライナズ・メディカル・センター |
マイクロrna−196の過剰発現によるc型肝炎ウイルス感染の治療
|
|
KR20110075019A
(ko)
|
2008-10-15 |
2011-07-05 |
인터뮨, 인크. |
치료용 항바이러스성 펩티드
|
|
WO2010049438A2
(en)
|
2008-10-30 |
2010-05-06 |
Innate Pharma |
Improved methods of using phosphoantigens for the treatment of diseases
|
|
EP2358439A1
(en)
|
2008-11-05 |
2011-08-24 |
Vertex Pharmaceuticals Incorporated |
Methods for treating hepatitis c virus infection
|
|
CN102223875A
(zh)
|
2008-11-21 |
2011-10-19 |
贝林格尔.英格海姆国际有限公司 |
口服给药的强效hcv抑制剂的药物组合物
|
|
EP2364309B1
(en)
|
2008-12-10 |
2014-10-01 |
Achillion Pharmaceuticals, Inc. |
New 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
|
|
EP2356236B1
(en)
|
2008-12-11 |
2015-07-29 |
Xiangxue Group (Hong Kong) Company Limited |
siRNA COMPOSITIONS AND METHODS FOR POTENTLY INHIBITING VIRAL INFECTION
|
|
CA2745284A1
(en)
|
2008-12-18 |
2010-06-24 |
F. Hoffmann-La Roche Ag |
Biomarkers for hcv treatment response
|
|
KR20110098849A
(ko)
|
2008-12-23 |
2011-09-01 |
파마셋 인코포레이티드 |
뉴클레오시드 유사체
|
|
CA2740193A1
(en)
|
2008-12-23 |
2010-07-01 |
Abbott Laboratories |
Anti-viral compounds
|
|
WO2010076788A2
(en)
|
2008-12-29 |
2010-07-08 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Methods of predicting responsiveness to interferon treatment and treating hepatitis c infection
|
|
US8840934B2
(en)
|
2009-01-02 |
2014-09-23 |
Rainbow Pharmaceutical Sa |
Uses of ammonium chloride
|
|
SG172921A1
(en)
|
2009-01-09 |
2011-08-29 |
Univ Cardiff |
Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections
|
|
RU2398582C1
(ru)
|
2009-01-19 |
2010-09-10 |
Государственное образовательное учреждение высшего профессионального образования "Санкт-Петербургская государственная медицинская академия им. И.М. Мечникова Федерального агентства по здравоохранению и социальному развитию" |
Способ лечения хронического вирусного гепатита с 1-генотипа с умеренной активностью и репликативностью
|
|
WO2010093843A2
(en)
|
2009-02-12 |
2010-08-19 |
Vertex Pharmaceuticals Incorporated |
Hcv combination therapies
|
|
AR075584A1
(es)
|
2009-02-27 |
2011-04-20 |
Intermune Inc |
COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
|
|
US8101643B2
(en)
|
2009-02-27 |
2012-01-24 |
Enanta Pharmaceuticals, Inc. |
Benzimidazole derivatives
|
|
WO2010101649A2
(en)
|
2009-03-05 |
2010-09-10 |
Pablo Gastaminza |
Sigma 1 receptor inhibition as a novel therapeutical approach against hepatitis c virus infection
|
|
EP2403537A1
(en)
|
2009-03-05 |
2012-01-11 |
Ascendis Pharma A/S |
Interferon alpha carrier prodrugs
|
|
MX2011010058A
(es)
|
2009-03-25 |
2011-10-11 |
Abbott Lab |
Compuestos antivirales y usos de los mismos.
|
|
CA2755023C
(en)
|
2009-03-25 |
2016-12-13 |
Abbott Laboratories |
Antiviral compounds and uses thereof
|
|
CN102459165B
(zh)
|
2009-04-15 |
2015-09-02 |
Abbvie公司 |
抗病毒化合物
|
|
ES2599979T3
(es)
|
2009-04-24 |
2017-02-06 |
Roche Innovation Center Copenhagen A/S |
Composiciones farmacéuticas para el tratamiento de pacientes de VHC que no responden al interferón
|
|
SG175328A1
(en)
|
2009-04-25 |
2011-11-28 |
Hoffmann La Roche |
Methods for improving pharmacokinetics
|
|
PT3309157T
(pt)
|
2009-05-13 |
2019-12-02 |
Gilead Pharmasset Llc |
Compostos antivirais
|
|
US8618076B2
(en)
|
2009-05-20 |
2013-12-31 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
|
TWI598358B
(zh)
|
2009-05-20 |
2017-09-11 |
基利法瑪席特有限責任公司 |
核苷磷醯胺
|
|
EP2432898B1
(en)
|
2009-05-21 |
2014-11-26 |
Merck Sharp & Dohme Corp. |
Genetic markers associated with interferon-alpha response
|
|
US8937150B2
(en)
|
2009-06-11 |
2015-01-20 |
Abbvie Inc. |
Anti-viral compounds
|
|
UA118080C2
(uk)
|
2009-06-11 |
2018-11-26 |
Еббві Айрленд Анлімітед Компані |
Противірусні сполуки
|
|
US9394279B2
(en)
|
2009-06-11 |
2016-07-19 |
Abbvie Inc. |
Anti-viral compounds
|
|
US20100324059A1
(en)
|
2009-06-23 |
2010-12-23 |
Gilead Sciences, Inc. |
Pharmaceutical compositions useful for treating hcv
|
|
AR077125A1
(es)
|
2009-06-23 |
2011-08-03 |
Gilead Sciences Inc |
Combinaciones farmaceuticas utiles para tratar el vhc
|
|
AR077139A1
(es)
|
2009-06-23 |
2011-08-03 |
Gilead Sciences Inc |
Composiciones farmaceuticas utiles para tratar el vch
|
|
AP2012006064A0
(en)
|
2009-06-26 |
2012-02-29 |
Romark Lab Lc |
Compounds and methods for treating influenza.
|
|
US8232246B2
(en)
|
2009-06-30 |
2012-07-31 |
Abbott Laboratories |
Anti-viral compounds
|
|
JP5607736B2
(ja)
|
2009-07-07 |
2014-10-15 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
C型肝炎ウイルスプロテアーゼ阻害剤のための医薬組成物
|
|
RU2400229C1
(ru)
|
2009-07-13 |
2010-09-27 |
Государственное образовательное учреждение высшего профессионального образования "Санкт-Петербургская государственная медицинская академия им. И.И. Мечникова Федерального агентства по здравоохранению и социальному развитию" |
СПОСОБ ЛЕЧЕНИЯ БОЛЬНЫХ ХРОНИЧЕСКИМ ВИРУСНЫМ ГЕПАТИТОМ С, ГЕНОТИПОМ 3а
|
|
US20110020272A1
(en)
|
2009-07-24 |
2011-01-27 |
Ulrich Schubert |
Combination therapy for treating hepatitis viral infection
|
|
AU2010277239A1
(en)
|
2009-07-31 |
2012-02-02 |
Centre Hospitalier Universitaire Vaudois |
Methods for diagnosing or predicting hepatitis C outcome in HCV infected patients
|
|
US20110027229A1
(en)
|
2009-07-31 |
2011-02-03 |
Medtronic, Inc. |
Continuous subcutaneous administration of interferon-alpha to hepatitis c infected patients
|
|
EP2470189A4
(en)
|
2009-08-27 |
2013-01-23 |
Merck Sharp & Dohme |
METHOD FOR PRODUCING PROTEASE INHIBITORS OF HEPATITIS C VIRUS
|
|
US20110086869A1
(en)
|
2009-09-24 |
2011-04-14 |
The Trustees Of Boston University |
Methods for treating viral disorders
|
|
US20110082182A1
(en)
|
2009-10-01 |
2011-04-07 |
Intermune, Inc. |
Therapeutic antiviral peptides
|
|
US8415374B2
(en)
|
2009-10-12 |
2013-04-09 |
Bristol-Myers Squibb Company |
Combinations of hepatitis C virus inhibitors
|
|
US9174988B2
(en)
|
2009-10-27 |
2015-11-03 |
Trustees Of Boston University |
Small molecule inhibitors of hepatitis C virus
|
|
WO2011056650A2
(en)
|
2009-10-27 |
2011-05-12 |
Michael Zasloff |
Methods and compositions for treating and preventing viral infections
|
|
EA201200650A1
(ru)
|
2009-10-30 |
2012-12-28 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Курсы комбинированного лечения вируса гепатита с, включающие bi201335, интерферон-альфа и рибавирин
|
|
AU2010325065A1
(en)
|
2009-11-09 |
2012-05-24 |
Merck Sharp & Dohme Corp. |
Markers associated with ribavirin-induced anemia
|
|
US20110117055A1
(en)
|
2009-11-19 |
2011-05-19 |
Macdonald James E |
Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds
|
|
WO2011066260A2
(en)
|
2009-11-25 |
2011-06-03 |
Michael Zasloff |
Formulations comprising aminosterols
|
|
AU2010333656B2
(en)
|
2009-12-18 |
2015-08-27 |
Boehringer Ingelheim International Gmbh |
HCV combination therapy
|
|
WO2011079016A1
(en)
|
2009-12-22 |
2011-06-30 |
Gilead Sciences, Inc. |
Methods of treating hbv and hcv infection
|
|
WO2011076807A2
(en)
|
2009-12-23 |
2011-06-30 |
Novartis Ag |
Lipids, lipid compositions, and methods of using them
|
|
RU2424794C1
(ru)
|
2009-12-30 |
2011-07-27 |
Государственное образовательное учреждение высшего профессионального образования "Уральская государственная медицинская академия Федерального агентства по здравоохранению и социальному развитию" (ГОУ ВПО УГМА Росздрава) |
Способ лечения врожденного гепатита с у детей первого года жизни
|
|
AU2011210795A1
(en)
|
2010-01-29 |
2012-08-02 |
Vertex Pharmaceuticals Incorporated |
Therapies for treating Hepatitis C virus infection
|
|
CN104771364B
(zh)
|
2010-03-10 |
2018-05-25 |
艾伯维巴哈马有限公司 |
固体组合物
|
|
US8530497B2
(en)
|
2010-03-11 |
2013-09-10 |
Boehringer Ingelheim International Gmbh |
Crystalline salts of a potent HCV inhibitor
|
|
PT2609923T
(pt)
|
2010-03-31 |
2017-08-30 |
Gilead Pharmasset Llc |
Processo para a cristalização de 2-(((s)- (perfluorofenoxi)(fenoxi)fosforil)amino)propanoato de (s)-isopropilo
|
|
JP2013528217A
(ja)
|
2010-06-07 |
2013-07-08 |
アッヴィ・インコーポレイテッド |
大環状c型肝炎セリンプロテアーゼ阻害薬
|
|
US20110306541A1
(en)
|
2010-06-10 |
2011-12-15 |
Gilead Sciences, Inc. |
Methods for treating hcv
|
|
NZ605440A
(en)
|
2010-06-10 |
2014-05-30 |
Abbvie Bahamas Ltd |
Solid compositions comprising an hcv inhibitor
|
|
US8592372B2
(en)
|
2010-06-29 |
2013-11-26 |
King Saud University Liver Disease |
Pharmaceutical composition and method of use to improve organ function
|
|
RU2429877C1
(ru)
|
2010-06-30 |
2011-09-27 |
Общество с ограниченной ответственностью "ИНГИЛС" |
Способ лечения хронического вирусного гепатита с
|
|
EP2593105A1
(en)
|
2010-07-14 |
2013-05-22 |
Vertex Pharmaceuticals Incorporated |
Palatable pharmaceutical composition comprising vx-950
|
|
US8895737B2
(en)
|
2010-07-16 |
2014-11-25 |
Shashank Shekhar |
Process for preparing antiviral compounds
|
|
WO2012015712A1
(en)
|
2010-07-30 |
2012-02-02 |
Schering Corporation |
Inhibition of cyp3a drug metabolism
|
|
US20120196272A1
(en)
|
2010-08-05 |
2012-08-02 |
Roche Molecular Systems, Inc. |
Prediction of HCV Viral Kinetics in Interferon-Free Treatment
|
|
US20120196794A1
(en)
|
2010-08-06 |
2012-08-02 |
Bristol-Myers Squibb Company |
Combinations of Hepatitis C Virus Inhibitors
|
|
BR112013005872A2
(pt)
|
2010-09-22 |
2019-09-24 |
Alios Biopharma Inc |
compostos, composição farmacêutica e respectivos usos
|
|
WO2012050850A1
(en)
|
2010-09-29 |
2012-04-19 |
Merck Sharp & Dohme Corp. |
Polycyclic heterocycle derivatives and methods of use thereof for the treatment of viral diseases
|
|
MA34547B1
(fr)
|
2010-09-30 |
2013-09-02 |
Boehringer Ingelheim Int |
Traitement d'association pour traiter une infection par le vhc
|
|
US20120107278A1
(en)
|
2010-10-29 |
2012-05-03 |
Pharmasset, Inc. |
Abbreviated hcv therapy for hcv infected patients with il28b c/c genotype
|
|
TWI451439B
(zh)
|
2010-12-10 |
2014-09-01 |
Phison Electronics Corp |
記憶體儲存裝置、其記憶體控制器與資料寫入方法
|
|
MX2013006828A
(es)
|
2010-12-16 |
2014-10-14 |
Abbvie Inc |
Compuestos antivirales.
|
|
MX2013006951A
(es)
|
2010-12-16 |
2013-10-03 |
Abbvie Inc |
Compuestos antivirales.
|
|
AU2011349844B2
(en)
|
2010-12-20 |
2017-06-01 |
Gilead Sciences, Inc. |
Combinations for treating HCV
|
|
CA2822357A1
(en)
|
2010-12-22 |
2012-06-28 |
Abbvie Inc. |
Hepatitis c inhibitors and uses thereof
|
|
KR20140003521A
(ko)
|
2010-12-30 |
2014-01-09 |
이난타 파마슈티칼스, 인코포레이티드 |
페난트리딘 매크로사이클릭 c형 간염 세린 프로테아제 억제제
|
|
EP2725902A4
(en)
|
2011-04-06 |
2015-06-24 |
Univ Princeton |
ANTIVIRAL COMBINATION THERAPY
|
|
US20140127159A1
(en)
|
2011-06-23 |
2014-05-08 |
Stella Aps |
HCV Combination Therapy
|
|
EP2726611A1
(en)
|
2011-06-30 |
2014-05-07 |
Stella ApS |
Hcv combination therapy
|
|
KR20140064765A
(ko)
|
2011-06-30 |
2014-05-28 |
스텔라 에이피에스 |
Hcv 조합 치료
|
|
WO2013024158A1
(en)
|
2011-08-17 |
2013-02-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combinations of protein kinase inhibitors and interferons or of protein kinase inhibitors and direct acting antivirals for the treatment and the prevention of hcv infection
|
|
WO2013024155A1
(en)
|
2011-08-17 |
2013-02-21 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Combinations of anti-hcv-entry factor antibodies and direct acting antivirals for the treatment and the prevention of hcv infection
|
|
WO2013025975A1
(en)
|
2011-08-17 |
2013-02-21 |
Glaxosmithkline Llc |
Combination treatments for hepatitis c
|
|
PH12014500386A1
(en)
|
2011-08-24 |
2019-10-07 |
Glaxosmithkline Llc |
Combination treatment for hepatitis c
|
|
PL2709613T5
(pl)
|
2011-09-16 |
2020-12-14 |
Gilead Pharmasset Llc |
Metody leczenia hcv
|
|
WO2013044030A1
(en)
|
2011-09-23 |
2013-03-28 |
Enanta Pharmaceuticals, Inc. |
2'-chloroacetylenyl substituted nucleoside derivatives
|
|
US8492386B2
(en)
|
2011-10-21 |
2013-07-23 |
Abbvie Inc. |
Methods for treating HCV
|
|
DE112012002748T5
(de)
|
2011-10-21 |
2014-07-31 |
Abbvie Inc. |
Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon
|
|
US8466159B2
(en)
|
2011-10-21 |
2013-06-18 |
Abbvie Inc. |
Methods for treating HCV
|
|
SE1450131A1
(sv)
|
2011-10-21 |
2014-05-07 |
Abbvie Inc |
DAA-kombinationsbehandling (t.ex. med ABT-072 eller ABT-333)för användning vid behandling av HCV
|
|
US20140328799A1
(en)
|
2011-10-31 |
2014-11-06 |
Steven S. Carroll |
Compositions useful for the treatment of viral diseases
|
|
US20130137084A1
(en)
|
2011-11-28 |
2013-05-30 |
Roche Molecular Systems, Inc. |
Single Nucleotide Polymorphism on Chromosome 15 That Predicts HCV Treatment Responses
|
|
US8889159B2
(en)
|
2011-11-29 |
2014-11-18 |
Gilead Pharmasset Llc |
Compositions and methods for treating hepatitis C virus
|
|
EP2794630A4
(en)
*
|
2011-12-22 |
2015-04-01 |
Alios Biopharma Inc |
SUBSTITUTED PHOSPHORTHIOAT NUCLEOTIDE ANALOGUE
|
|
EP2890704B1
(en)
*
|
2012-08-31 |
2018-02-28 |
Novartis AG |
2'-ethynyl nucleoside derivatives for treatment of viral infections
|
|
CN104780920A
(zh)
|
2012-09-18 |
2015-07-15 |
艾伯维公司 |
用于治疗丙型肝炎的方法
|
|
US20140080868A1
(en)
|
2012-09-18 |
2014-03-20 |
Abbvie Inc. |
Methods for Treating HCV
|
|
CA2891125A1
(en)
*
|
2012-11-19 |
2014-05-22 |
Merck Sharp & Dohme Corp. |
2 -alkynyl substituted nucleoside derivatives for treating viral diseases
|
|
GEP201706757B
(en)
|
2012-12-21 |
2017-10-25 |
Alios Biopharma Inc |
Substituted nucleosides, nucleotides and analogs thereof
|
|
WO2014100498A1
(en)
*
|
2012-12-21 |
2014-06-26 |
Alios Biopharma, Inc. |
Substituted nucleosides, nucleotides and analogs thereof
|
|
EP3213750B1
(en)
|
2013-03-14 |
2020-08-12 |
AbbVie Inc. |
Combination of two antivirals for treating hepatitis c
|
|
RS56735B1
(sr)
|
2013-03-14 |
2018-03-30 |
Abbvie Inc |
Kombinacija direktno delujućih antivirusnih sredstava i ribavirina za lečenje pacijenata sa hcv
|
|
HK1224229A1
(zh)
*
|
2013-06-26 |
2017-08-18 |
Alios Biopharma, Inc. |
取代的核苷,核苷酸及其类似物
|
|
US10023626B2
(en)
*
|
2013-09-30 |
2018-07-17 |
Modernatx, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
EP3055319A4
(en)
*
|
2013-10-11 |
2018-01-10 |
Alios Biopharma, Inc. |
Substituted nucleosides, nucleotides and analogs thereof
|
|
EP3082808A1
(en)
|
2013-12-19 |
2016-10-26 |
AbbVie Inc. |
Methods for treating liver transplant recipients
|
|
TN2016000566A1
(en)
*
|
2014-06-24 |
2018-04-04 |
Alios Biopharma Inc |
Substituted nucleosides, nucleotides and analogs thereof
|
|
LT3160476T
(lt)
*
|
2014-06-24 |
2021-04-12 |
Janssen Biopharma, Inc. |
Pakeistieji nukleozidai, nukleotidai ir jų analogai, skirti naudoti virusinių infekcijų gydyme
|
|
WO2016014527A2
(en)
*
|
2014-07-21 |
2016-01-28 |
Achillion Pharmaceuticals, Inc. |
Stabilized nucleotides for medical treatment
|
|
MA41441A
(fr)
*
|
2014-12-19 |
2017-12-12 |
Alios Biopharma Inc |
Nucléosides substitués, nucléotides et analogues de ceux-ci
|
|
US9980865B2
(en)
*
|
2015-03-30 |
2018-05-29 |
Christopher Miranda |
Elevating wheelchair
|
|
EA201892448A1
(ru)
*
|
2016-04-28 |
2019-06-28 |
Эмори Юниверсити |
Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
|